MERCK AG 1991SALES RISE 12%

17 May 1992

Consolidated drug and chemical sales of Merck AG in Zug, Switzerland, rose 12% in 1991 to 2.18 billion Swiss francs ($1.44 billion). Operating profits improved 21% to 316 million francs ($209.0 million).

Taxes for 1991 were higher than the previous year (up 28%) and higher spending on restructuring in the UK meant that group net profits fell back 4% to 138 million francs ($91.3 million).

However, Merck was able to boost sales again in the first quarter of 1992 by about 10%, according to provisional figures, with pharmaceutical sales up 15% to 998 million francs ($660.1 million).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight